Trial Radar AI | ||
|---|---|---|
Clinical Trial NCT07244003 (MESSAGE) for T2DM (Type 2 Diabetes Mellitus) is recruiting. See the Trial Radar Card View and AI discovery tools for all the details. Or ask anything here. | ||
One study matched filter criteria
Card View
Efficacy and Safety of the Met+SGLT-2i+GLP-1RA in Patients With Type 2 Diabetes With Poor Glycemic Control (MESSAGE) Phase 4 430 Combination Therapy
Clinical Trial NCT07244003 (MESSAGE) is designed to study Treatment for T2DM (Type 2 Diabetes Mellitus). It is a Phase 4 interventional study that is recruiting, having started on March 29, 2025, with plans to enroll 430 participants. Led by Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., it is expected to complete by June 30, 2028. The latest data from ClinicalTrials.gov was last updated on November 24, 2025.
Brief Summary
The main objective of this study is to compare the efficacy and safety of the triple combination therapy of Met/SGLT-2i/GLP-1RA or other oral antidiabetic drugs in patients with type 2 diabetes exhibiting poor glycemic control.
Official Title
Efficacy and Safety of the Triple Combination Therapy of Met/SGLT-2i/GLP-1RA or Other Oral Antidiabetic Drugs in Patients With Type 2 Diabetes Exhibiting Poor Glycemic Control
Conditions
T2DM (Type 2 Diabetes Mellitus)Other Study IDs
- MESSAGE
- HD-LLPHYJ-LC-1
NCT ID Number
Start Date (Actual)
2025-03-29
Last Update Posted
2025-11-24
Completion Date (Estimated)
2028-06-30
Enrollment (Estimated)
430
Study Type
Interventional
PHASE
Phase 4
Status
Recruiting
Primary Purpose
Treatment
Design Allocation
Randomized
Interventional Model
Parallel
Masking
None (Open Label)
Arms / Interventions
| Participant Group/Arm | Intervention/Treatment |
|---|---|
ExperimentalMet+SGLT-2i+GLP-1RA Metformin+Ganagliflozin+Liraglutide | Metformin The dosage of metformin hydrochloride was consistent with baseline. ganagliflozin Ganagliflozin tablet : 50mg/d. liraglutide Liraglutide injection: 0.6 mg/d for the first week, 1.2 mg/d for the second week, and 1.8 mg/d after the third week. |
Active ComparatorTriple Therapy of Other Oral Antidiabetic Drugs Building upon the previously stable treatment regimen, the addition of 1-2 oral hypoglycemic agents (excluding SGLT-2 inhibitors and oral GLP-1 receptor agonists) constitutes a triple oral hypoglycemic regimen. | Triple Therapy of Other Oral Antidiabetic Drugs The dosage of metformin hydrochloride was consistent with baseline. The usage and dosage of other hypoglycemic drugs were referred to their respective instructions. |
Primary Outcome Measures
Secondary Outcome Measures
| Outcome Measure | Measure Description | Time Frame |
|---|---|---|
The change of HbA1c compared to the baseline | from baseline to week 24 |
| Outcome Measure | Measure Description | Time Frame |
|---|---|---|
The proportion of participants achieving HbA1c, blood pressure, and cholesterol targets | HbA1c ≤ 7.0% Blood pressure \< 130/80 mmHg For subjects without ASCVD, LDL-C \< 2.6 mmol/L; for subjects with ASCVD, LDL-C \< 1.8 mmol/L (\< 70 mg/dL) | week 24 |
The proportion of patients achieving HbA1c target without hypoglycemia or weight gainning | HbA1c target ≤ 7.0% The definition of hypoglycemia is: Blood glucose \< 70 mg/dL ( \< 3.9 mmol/L), regardless of whether there are symptoms of hypoglycemia. | week 24 |
The changes of waist circumference and hip circumference compared to the baseline | from baseline to week 24 | |
The changes of fasting blood glucose, 2-hour post-meal blood glucose, fasting glucagon, fasting insulin, insulin resistance index (HOMA-IR) compared to the baseline | from baseline to week 24 | |
Changes in systolic and diastolic blood pressure compared to the baseline | from baseline to week 24 | |
The changes in urine albumin-to-creatinine ratio (UACR) compared to the baseline | from baseline to week 24 | |
The changes of body mass compared to the baseline | from baseline to 24 week | |
The changes of BMI compared to the baseline | from baseline to 24 week | |
The changes of waist-hip ratio, waist-to-height ratio compared to the baseline | from baseline to 24 week |
Participation Assistant
Eligibility Criteria
Eligible Ages
Adult, Older Adult
Minimum Age
18 Years
Eligible Sexes
All
- Meet the diagnostic criteria for type 2 diabetes (refer to the Chinese Guidelines for the Prevention and Treatment of Type 2 Diabetes (2020 edition)); -Age: 18-75 years old (including the threshold), male or female;
- Body mass index (BMI) ≥20kg/m² ;
- Patients who took 1000mg or more of metformin in combination with or without another oral hypoglycemic agent (except SGLT-2i and oral GLP-1RA) for at least 8 weeks before screening and had poor blood glucose control (centralized detection of HBA1C >=7.5% and<=11.0%);
- Volunteer to participate in this study and sign informed consent.
- Patients with type 1 diabetes or other special types of diabetes;
- Patients with acute complications of ketoacidosis/hyperglycemic hyperosmolar state/lactic acidosis within 6 months before screening
- Those who have used GLP-1RA and SGLT-2i drugs within 12 weeks before screening, or have used GLP-1RA and SGLT-2i drugs in the past and discontinued due to poor efficacy
- Those who received insulin treatment within the previous week
- Those who have a history of chronic or acute pancreatitis before screening, or have clinical manifestations of pancreatitis at the time of screening, or fasting triglycerides > 5.7 mmol/L during the screening period
- Liver function impairment at screening: alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 3 UNL, or total blood bilirubin (TBIL) > 2 UNL;
- Renal impairment at screening: calculated according to the CKD-EPI formula, eGFR≤45 mL/min/1.73m² or serum creatinine≥1.5 UNL;
- Patients with a past or family history of medullary thyroid cancer (MTC) and patients with multiple endocrine neoplasia syndrome type 2 (MEN2)
- Female subjects who are currently pregnant, breastfeeding, or have a pregnancy plan during the study period
- Those who have a history of hypersensitivity reaction to metformin, gapagliflozin, liraglutide injection and other drugs used in research and their excipients or have contraindications to the study drugs;
- Those who have participated in other drug clinical trials within 3 months before screening; 21. Subjects who are unable to comply with the protocol under the judgment of the investigator, and those who have other serious physical or psychological diseases that may affect the effectiveness and safety.
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.Study Central Contact
Contact: Xiaofen Qian, +86-0571-89908582, [email protected]
Contact: Wanting Zhang, +86-0571-89905517, [email protected]
1 Study Locations in 1 Countries
Tianjin Municipality
Tianjin Medical University General Hospital, Tianjin, Tianjin Municipality, China
Ming Liu, Contact, +86 183 2201 7516, [email protected]
Recruiting